

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

5

**Complete if Known**

Application Number	10/561,618
Filing Date	05/05/2006
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Tracy Ann Vivlemore
Attorney Docket Number	CORE0005USA

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
/TV/ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓	AA	US-5,484,908	01-16-1996	Froehler et al.	
	AB	US-5,898,031	04-29-1999	Crooke	
	AC	US-6,005,087	12-21-1999	Cook et al.	
	AD	US-6,107,094	08-22-2000	Crooke	
	AE	US-2004/0259247	12-23-2004	Tuschl et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
/TV/ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓	AF	WO 99/32619 A1	07-01-1999	Carnegie Institute		
	AG	WO 00/44895 A1	08-03-2000	Kreutzer et al.		
	AH	WO 00/44914 A1	08-03-2000	Medical College		
	AI	WO 00/49035 A1	08-24-2000	General Hospital		
	AJ	WO 00/63364 A2	10-26-2000	American Home		
	AK	WO 01/29058 A1	04-26-2001	University of Massachusetts		
	AL	WO 01/36641 A2	05-25-2001	Chiron Corp.		
	AM	WO 01/36646 A1	05-25-2001	Cancer Res.		
	AN	WO 01/48183 A2	07-05-2001	Devgen NV		
	AO	WO 01/75164 A2	10-11-2001	Whitehead Inst.		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **2** of **5****Complete if Known**

Application Number	10/561,618
Filing Date	05/05/2006
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Tracy Ann Vivlenmore
Attorney Docket Number	CORE0005USA

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/TV/	AP	BASS, B. L., "Double-Stranded RNA as a Template for Gene Silencing," <i>Cell</i> (2000) 101(3):235-238.	
	AQ	BOUTLA A. et al., "Short 5'-phosphorylated double-stranded RNAs induce RNA interference in <i>Drosophila</i> ," <i>Current Biology</i> (2001) 11(22):1776-1780.	
	AR	BRAASCH, D. A. et al., "RNA Interference in Mammalian Cells by Chemically-Modified RNA," <i>Biochemistry</i> (2003) 42(26):7967-7975.	
	AS	BRANTL, S., "Antisense-RNA regulation and RNA interference," <i>Biochimica et Biophysica Acta</i> (2002) 1575(1-3):15-25.	
	AT	BUHR, C. A. et al., "Oligodeoxynucleotides containing C-7 propyne analogs of 7-deaza-2'-deoxyguanosine and 7-deaza-2'-deoxyadenosine," <i>Nucleic Acids Research</i> (1996) 24(15):2974-2980.	
	AU	CHIU, Y.-L. et al., "siRNA function in RNAi: A chemical modification analysis," <i>RNA</i> (2003) 9(9):1034-1048.	
	AV	COGONI, C. et al., "Post-transcriptional gene silencing across kingdoms," <i>Curr Opin Genet Dev.</i> (2000) 10(6):638-643.	
	AW	ELBASHIR, S. M. et al., "RNA interference is mediated by 21- and 22-nucleotide RNAs," <i>Genes Dev.</i> (2001) 15(2):188-200.	
	AX	ELBASHIR, S. M. et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> (2001) 411(6836):494-498.	
	AY	ELBASHIR, S. M. et al., "Functional anatomy of siRNAs for mediating efficient RNAi in <i>Drosophila melanogaster</i> embryo lysate," <i>EMBO</i> (2001) 20(23):6877-6887.	
	AZ	FIRE, A. et al., "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> ," <i>Nature</i> (1998) 391:806-811.	
	BA	GALLO, M. et al., "2'-C-Methyluridine phosphoramidite: a new building block for the preparation of RNA analogues carrying the 2'-hydroxyl group," <i>Tetrahedron</i> (2001) 57(27):5707-5713.	
	BB	GUILLERM, D. et al., "Synthesis of 4'-fluoroadenosine as an inhibitor of S-adenosyl-L-homocysteine hydrolase," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> (1995) 5(14):1455-1460.	
↓	BC	GUO, S. et al., " <i>par-1</i> , a Gene Required for Establishing Polarity in <i>C. elegans</i> Embryos, Encodes a Putative Ser/Thr Kinase That Is Asymmetrically Distributed," <i>Cell</i> (1995) 81(4):611-620.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 5

**Complete If Known**

Application Number	10/561,618
Filing Date	05/05/2006
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Tracy Ann Vivimore
Attorney Docket Number	CORE0005USA

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/TV/	BD	GURU, T., "A silence that speaks volumes," <i>Nature</i> (2000) 404:804-808.	
	BE	GUTIERREZ, A. J. et al., "Antisense Gene Inhibition by C-5-Substituted Deoxyuridine-Containing Oligodeoxynucleotides," <i>Biochemistry</i> (1997) 36(4):743-748.	
	BF	HARRY O'KURU, R. E. et al., "A Short, Flexible Route toward 2'-C-Branched Ribonucleosides," <i>J. Org. Chem.</i> (1997) 62(6):1754-1759.	
	BG	JACOBSON, K. A. et al., "Methanocarpa Analogues of Purine Nucleosides as Potent and Selective Adenosine Receptor Agonists," <i>J. Med. Chem.</i> (2000) 43(11):2196-2203.	
	BH	JORGENSEN, R. A. et al., "Chalcone synthase cosuppression phenotypes in petunia flowers: comparison of sense vs. antisense constructs and single-copy vs. complex T-DNA sequences," <i>Plant Mol. Biol.</i> (1996) 31(5):957-973.	
	BI	KAWASAKI, A. M. et al., "Uniformly Modified 2'-Deoxy-2'-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets," <i>J. Med. Chem.</i> (1993) 36(7):831-841.	
	BJ	KHVOROVA, A. et al., "Functional siRNAs and miRNAs Exhibit Strand Bias," <i>Cell</i> (2003) 115(2):209-216.	
	BK	KURRECK, J., "Antisense technologies, Improvement through novel chemical modifications," <i>Eur. J. Biochem.</i> (2003) 270(8):1628-1644.	
	BL	LEE, K. et al., "Ring-Constrained (N)-Methanocarpa Nucleosides as Adenosine Receptor Agonists: Independent 5'-Uronamide and 2'-Deoxy Modifications," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> (2001) 11(10):1333-1337.	
	BM	LIN, K.-Y. et al., "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acids," <i>J. Am. Chem. Soc.</i> (1998) 120(33):8531-8532.	
	BN	MARTINEZ, J. et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <i>Cell</i> (2002) 110(5):563-574.	
	BO	MELLITZER, G. et al., "Spatial and temporal 'knock down' of gene expression by electroporation of double-stranded RNA and morpholinos into early postimplantation mouse embryos," <i>Mechanisms of Development</i> (2002) 118(1-2):57-63.	
↓	BP	MONTGOMERY, M. K. et al., "RNA as a target of double-stranded RNA-mediated genetic interference in <i>Caenorhabditis elegans</i> ," <i>Proc. Natl. Acad. Sci. USA</i> (1998) 95(26):15502-15507.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 5

**Complete if Known**

Application Number	10/561,618
Filing Date	05/05/2006
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Tracy Ann Vivimore
Attorney Docket Number	CORE0005USA

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/TV/	BQ	MORITA, K. et al., "2'-O,4'-C-Ethylene-Bridged Nucleic Acids (ENA): Highly Nuclease-Resistant and Thermodynamically Stable Oligonucleotides for Antisense Drug," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> (2002) 12(1):73-76.	
	BR	MOULDS, C. et al., "Site and Mechanism of Antisense Inhibition by C-5 Propyne Oligonucleotides," <i>Biochemistry</i> (1995) 34(15):5044-5053.	
	BS	NAPOLI, C. et al., "Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans," <i>Plant Cell</i> (1990) 2(4):279-289.	
	BT	NISHIKURA, K. et al., "A Short Primer on RNAi: RNA-Directed RNA Polymerase Acts as a Key Catalyst," <i>Cell</i> (2001) 107(4):415-418.	
	BU	OWEN, G. R. et al., "4'-Substituted Nucleosides. 3. Synthesis of Some 4'-Fluorouridine Derivatives," <i>J. Org. Chem.</i> (1976) 41(18):3010-3017.	
	BV	PARRISH, S. et al., "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," <i>Molecular Cell</i> (2000) 6(5):1077-1087.	
	BW	SCHWARZ, D. S. et al., "Evidence that siRNAs Function as Guides, Not Primers, in the <i>Drosophila</i> and Human RNAi Pathways," <i>Molecular Cell</i> (2002) 10(3):537-548.	
	BX	SCHWARZ, D. S. et al., "Asymmetry in the Assembly of the RNAi Enzyme Complex," <i>Cell</i> (2003) 115(2):199-208.	
	BY	SOUTSCHEK, J. et al., "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs," <i>Nature</i> (2004) 432(7014):173-178.	
	BZ	SINGH, S. K. et al., "LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition," <i>Chem Commun</i> (1998) (4):455-456.	
	CA	TABARA, H. et al., "RNAi in <i>C. elegans</i> : Soaking in the Genome Sequence," <i>Science</i> (1998) 282(5388):430-431.	
	CB	TANG, X.-Q. et al., "2'-C-Branched Ribonucleosides: Synthesis of the Phosphoramidite Derivatives of 2'-C-β-Methylcytidine and Their Incorporation into Oligonucleotides," <i>J. Org. Chem.</i> (1999) 64(3):747-754.	
	CC	TIJSTERMAN, M. et al., "RNA Helicase MUT-14-Dependent Gene Silencing Triggered in <i>C. elegans</i> by Short Antisense RNAs," <i>Science</i> (2002) 295(5555):694-697.	
↓	CD	TIMMONS, L. et al., "Specific interference by ingested dsRNA," <i>Nature</i> (1998) 395(6705):854.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet	5	of	5
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	10/561,618
<b>Filing Date</b>	05/05/2006
<b>First Named Inventor</b>	Brenda F. Baker
<b>Art Unit</b>	1635
<b>Examiner Name</b>	Tracy Ann Vivlmore
<b>Attorney Docket Number</b>	CORE0005USA

### NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature	/Tracy Vivlemore/	Date Considered	06/21/2007
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*